Observe Medical ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates

Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") earlier today, on 9 February 2022, regarding the commencement of the subscription period in the rights issue (the "Rights Issue"). Please see the attached notifications of trade for information regarding the primary insiders' and their close associates' receipt of subscription rights in the Rights Issue. For further information about the Company, please contact: Björn Larsson, CEO of Observe Medical, Mobile: +46 76 620 17 25 E-mail: bjorn.larsson@observemedical.com Per Arne Nygård, CFO of Observe Medical, Mobile: +47 411 04 345 E-mail: perarne.nygard@observemedical.com For information about the Rights Issue please contact the Managers: Carnegie AS, tel.: +47 22 00 93 40 DNB Markets, tel.: +47 23 26 81 01 About Observe Medical Observe Medical develops and markets and sells innovative hospital products that contribute to increased patient safety and a more efficient care system. The company's ambition is to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in the areas of Urine measurement, Anesthesiology/ICUs and wound care, in combination with targeted M&A. The company's headquarter is in Oslo, Norway and its operations is based out of Gothenburg, Sweden. Observe Medical has a direct sales organization in the Nordics and a distributor network internationally. Observe Medical's product Sippi® is the only automated digital urine meter with possibility for wireless data transfer to the hospital patient data management systems and hinders bacterial migration that can lead to urinary infections (SippCoat®). Sippi® is CE marked and is currently being launched with focus on selected markets and hospitals in Nordics and in Europe.